Azenta Life Sciences
Unrivaled sample exploration and management that helps life science companies bring impactful therapies to market faster
Unrivaled sample exploration and management that helps life science companies bring impactful therapies to market faster
Azenta Life Sciences is a prominent player in the biotechnology industry, offering unparalleled sample exploration and management services to expedite the delivery of impactful therapies to the market. With its last investment of $500.00M in Post-IPO Equity from JP Morgan Chase on 23 November 2022, Azenta has solidified its position as a leading provider of life sciences solutions. The company, founded in 1978, is headquartered in Burlington, MA, and operates across North America, Europe, and Asia. Azenta's full suite of reliable cold-chain sample management solutions and genomic services cater to top pharmaceutical, biotech, academic, and healthcare institutions globally, contributing to breakthroughs in areas such as drug development, clinical research, and advanced cell therapies. For more details, please visit www.azenta.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $500.00M | 1 | JP Morgan Chase | 23 Nov 2022 |
| Venture Round | $5.85M | 1 | Brooks Automation | 12 Mar 2014 |
| Venture Round | $2.50M | 1 |
|
04 Dec 2012 |
No recent news or press coverage available for Azenta Life Sciences.
We care about your data, and we'd love to use cookies make your experience better.
